---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-090311"
form_type: "8-K"
ticker: "AXSM"
cik: "0001579428"
company_name: "Axsome Therapeutics, Inc."
filed_at: "2024-08-05T23:59:59+00:00"
generated_at: "2026-05-31T13:07:14.305500+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Axsome Q2 revenue $87.2M (+87% YoY); Auvelity sales $65.0M (+135%)

## Summary
- Total net product revenue $87.2M, up 87% YoY; Auvelity $65.0M (+135%), Sunosi $22.1M (+16%).
- Net loss $79.3M ($1.67 per share) vs $67.2M ($1.54) in Q2 2023; cash $315.7M.
- NDA for AXS-07 in migraine resubmitted; NDA submission for AXS-14 in fibromyalgia expected Q3 2024.
- Patent litigation with Unichem settled; generic Sunosi entry allowed no earlier than June 30, 2042.
- Anticipated topline results: AXS-05 (AD agitation), solriamfetol (ADHD), AXS-12 (narcolepsy) in 2H 2024.

## SEC filing metadata
- accession: 0000950170-24-090311
- form_type: 8-K
- ticker: AXSM
- cik: 0001579428
- company_name: Axsome Therapeutics, Inc.
- filed_at: 2024-08-05T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1579428/000095017024090311/0000950170-24-090311-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1579428/000095017024090311/axsm-20240805.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-090311
- JSON: https://secwatch.observer/filing/0000950170-24-090311.json
- Plain text: https://secwatch.observer/filing/0000950170-24-090311.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.